LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Aandelen Lijst・Puma Biotechnology Inc

Puma Biotechnology Inc

Gesloten

SectorGezondheidszorg

7.4 -0.54

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.37

Max

7.68

Belangrijke statistieken
By Trading Economics
Inkomsten	3M 12M
Verkoop	21M 76M
K/W Sectorgemiddelde	12.344 49.8
Winstmarge	15.633
Werknemers	179
EBITDA	13M 27M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-32.89% downside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	25M 383M
Vorige openingsprijs	7.94
Vorige sluitingsprijs	7.4

Nieuwssentiment

By Acuity

50%

187 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

3.07 / 3.075 Steun & Weerstand

Puma Biotechnology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mei 2026, 23:41 UTC

Winsten

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mei 2026, 21:40 UTC

Winsten

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mei 2026, 23:34 UTC

Marktinformatie

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mei 2026, 23:13 UTC

Winsten

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mei 2026, 23:13 UTC

Winsten

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mei 2026, 23:12 UTC

Winsten

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mei 2026, 23:11 UTC

Winsten

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mei 2026, 23:07 UTC

Winsten

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mei 2026, 23:06 UTC

Winsten

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mei 2026, 23:06 UTC

Winsten

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mei 2026, 23:05 UTC

Winsten

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mei 2026, 23:04 UTC

Winsten

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mei 2026, 22:50 UTC

Winsten

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mei 2026, 22:25 UTC

Marktinformatie

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mei 2026, 22:11 UTC

Winsten

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mei 2026, 22:11 UTC

Winsten

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mei 2026, 22:05 UTC

Marktinformatie

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mei 2026, 21:58 UTC

Winsten

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mei 2026, 21:47 UTC

Marktinformatie

Winsten

Costco Posts 13% Sales Growth in April -- Market Talk

6 mei 2026, 21:46 UTC

Winsten

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mei 2026, 21:40 UTC

Winsten

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mei 2026, 21:35 UTC

Marktinformatie

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mei 2026, 21:32 UTC

Populaire aandelen

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mei 2026, 21:29 UTC

Winsten

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer Vergelijking

Prijswijziging

Puma Biotechnology Inc Prognose

Koersdoel

By TipRanks

-32.89% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 5 USD -32.89%

Hoogste 5 USD

Laagste 5 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Puma Biotechnology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Puma Biotechnology Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.07 / 3.075Steun & Weerstand

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

187 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.